BOOM
Recent additions may not be included but will usually appear in 24 hrs or less.
| Rational | Source |
|---|---|
|
The suppressive effect of bifidobacteria on Bacteroides vulgatus, a putative pathogenic microbe in inflammatory bowel disease. ✅
Microbiology and immunology (Microbiol Immunol ) Vol: 47 Issue 6 Pages: 371-8 Pub: 2003 Epub: Authors Shiba T , Aiba Y , Ishikawa H , Ushiyama A , Takagi A , Mine T , Koga Y , |
|
|
The effect of synbiotics Bifidobacterium infantis and milk oligosaccharides on shaping gut microbiota community structure and NASH treatment. ✅
Go to Publication ✅
Data in brief (Data Brief ) Vol: 19 Issue Pages: 1025-1029 Pub: 2018 Aug Epub: 2018 May 24 Authors Jena PK , Sheng L , Nagar N , Wu C , Barile D , Mills DA , Wan YY , |
|
|
Oral administration of Bifidobacterium longum and Bifidobacterium infantis ameliorates cefcapene pivoxil-induced attenuation of anti-programmed cell death protein-1 antibody action in mice. ✅
Go to Publication ✅
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (Biomed Pharmacother ) Vol: 182 Issue Pages: 117749 Pub: 2025 Jan Epub: 2024 Dec 23 Authors Funayama E , Hosonuma M , Tajima K , Isobe J , Baba Y , Murayama M , Narikawa Y , Toyoda H , Tsurui T , Maruyama Y , Sasaki A , Amari Y , Yamazaki Y , Nakashima R , Uchiyama J , Nakano R , Shida M , Sasaki A , Udaka Y , Oguchi T , Sambe T , Kobayashi S , Tsuji M , Kiuchi Y , Kim YG , Wada S , Tsunoda T , Akiyama M , Nobe K , Kuramasu A , Yoshimura K , |
|
|
Oral administration of Bifidobacterium longum and Bifidobacterium infantis ameliorates cefcapene pivoxil-induced attenuation of anti-programmed cell death protein-1 antibody action in mice. ✅
Go to Publication ✅
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (Biomed Pharmacother ) Vol: 182 Issue Pages: 117749 Pub: 2025 Jan Epub: 2024 Dec 23 Authors Funayama E , Hosonuma M , Tajima K , Isobe J , Baba Y , Murayama M , Narikawa Y , Toyoda H , Tsurui T , Maruyama Y , Sasaki A , Amari Y , Yamazaki Y , Nakashima R , Uchiyama J , Nakano R , Shida M , Sasaki A , Udaka Y , Oguchi T , Sambe T , Kobayashi S , Tsuji M , Kiuchi Y , Kim YG , Wada S , Tsunoda T , Akiyama M , Nobe K , Kuramasu A , Yoshimura K , |
|
|
Oral administration of Bifidobacterium longum and Bifidobacterium infantis ameliorates cefcapene pivoxil-induced attenuation of anti-programmed cell death protein-1 antibody action in mice. ✅
Go to Publication ✅
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (Biomed Pharmacother ) Vol: 182 Issue Pages: 117749 Pub: 2025 Jan Epub: 2024 Dec 23 Authors Funayama E , Hosonuma M , Tajima K , Isobe J , Baba Y , Murayama M , Narikawa Y , Toyoda H , Tsurui T , Maruyama Y , Sasaki A , Amari Y , Yamazaki Y , Nakashima R , Uchiyama J , Nakano R , Shida M , Sasaki A , Udaka Y , Oguchi T , Sambe T , Kobayashi S , Tsuji M , Kiuchi Y , Kim YG , Wada S , Tsunoda T , Akiyama M , Nobe K , Kuramasu A , Yoshimura K , |
|
|
Oral administration of Bifidobacterium longum and Bifidobacterium infantis ameliorates cefcapene pivoxil-induced attenuation of anti-programmed cell death protein-1 antibody action in mice. ✅
Go to Publication ✅
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (Biomed Pharmacother ) Vol: 182 Issue Pages: 117749 Pub: 2025 Jan Epub: 2024 Dec 23 Authors Funayama E , Hosonuma M , Tajima K , Isobe J , Baba Y , Murayama M , Narikawa Y , Toyoda H , Tsurui T , Maruyama Y , Sasaki A , Amari Y , Yamazaki Y , Nakashima R , Uchiyama J , Nakano R , Shida M , Sasaki A , Udaka Y , Oguchi T , Sambe T , Kobayashi S , Tsuji M , Kiuchi Y , Kim YG , Wada S , Tsunoda T , Akiyama M , Nobe K , Kuramasu A , Yoshimura K , |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
